Among these, core-binding factor (CBF) AMLs are characterized by balanced translocations affecting the transcription factor CBF subunits and are divided into two subtypes; inv(16)(p13.1q22)/t(16;16)(p13.1;q22) and t(8;21)(q22;q22.1) (AML t(8;21)), resulting in the fusion genes CBFB-MYH11 and RUNX1-RUNX1T1 [1]. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.